Arcadia Biosciences flagged for Nasdaq equity shortfall
Arcadia Biosciences has fallen below Nasdaq’s minimum stockholders’ equity requirement and must submit a compliance plan by October 15, 2026 to avoid potential delisting.
Rhea-AI Filing Summary
Arcadia Biosciences, Inc. (RKDA) reports that on August 31, 2026 it received a notice from Nasdaq’s Listing Qualifications Department that its stockholders’ equity no longer meets the Nasdaq Capital Market’s continued listing standard requiring at least $2,500,000 of stockholders’ equity.
Arcadia reported stockholders’ equity of $633,000 as of June 30, 2026 and also does not meet Nasdaq’s alternative market value or net income criteria, so it is currently out of compliance. The common stock continues to trade on the Nasdaq Capital Market while the company has 45 days, until October 15, 2026, to submit a plan to regain compliance. If Nasdaq accepts the plan, Arcadia may receive up to 180 days from the notice date to demonstrate compliance, but there is no assurance the plan will be accepted or that compliance will be achieved, and an appeal process is available if a plan is rejected.
Positive
- None.
Negative
- Arcadia’s stockholders’ equity is only $633,000, far below Nasdaq’s $2,500,000 minimum Stockholders’ Equity Requirement for continued listing.
- The company also fails Nasdaq’s alternative criteria for market value of listed securities and net income from continuing operations, heightening delisting risk.
- Nasdaq’s notice triggers a short 45-day window to submit an acceptable compliance plan, with no assurance that Nasdaq will accept it or that compliance will be regained.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Reported stockholders’ equity: $633,000
Nasdaq Stockholders’ Equity Requirement: $2,500,000
Plan submission window: 45 days
+3 more
6 metrics
Reported stockholders’ equity
$633,000
As of June 30, 2026 per the Form 10-Q
Nasdaq Stockholders’ Equity Requirement
$2,500,000
Minimum stockholders’ equity required under Nasdaq Listing Rule 5550(b)(1)
Plan submission window
45 days
Time from August 31, 2026 notice to submit plan, until October 15, 2026
Potential extension period
180 days
Maximum extension from the date of the Nasdaq notice if a plan is accepted
Notice date from Nasdaq
August 31, 2026
Date Nasdaq Listing Qualifications Department sent the deficiency letter
Plan deadline
October 15, 2026
Deadline for Arcadia to submit a compliance plan to Nasdaq
Key Terms
Nasdaq Capital Market, Stockholders’ Equity Requirement, Listing Qualifications Department, market value of listed securities, +2 more
6 terms
Nasdaq Capital Market market
"did not meet the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Stockholders’ Equity Requirement financial
"the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
Listing Qualifications Department regulatory
"received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC"
A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.
market value of listed securities financial
"the Company does not meet the alternatives of market value of listed securities or net income"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
net income from continuing operations financial
"does not meet the alternatives of market value of listed securities or net income from continuing operations"
Net income from continuing operations is the profit a company earns from its ongoing, day-to-day business after paying costs, interest and taxes, excluding results from businesses it has sold or closed and one-time gains or losses. Investors care because it shows the company's recurring earning power—like comparing a regular paycheck to a one-off bonus—and gives a clearer picture of sustainable profits used to value the business and judge management performance.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of Section 27A of the Securities Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
Why did Arcadia Biosciences (RKDA) receive a Nasdaq deficiency notice?
Arcadia received a Nasdaq notice on August 31, 2026 because its stockholders’ equity was $633,000 as of June 30, 2026, below the Nasdaq Capital Market’s $2,500,000 minimum, and it also did not meet the market value or net income alternative standards.
Is Arcadia Biosciences (RKDA) being delisted from Nasdaq now?
No. The notice has no immediate impact on Arcadia’s listing. Its common stock will continue to trade on the Nasdaq Capital Market while the company works through Nasdaq’s compliance process and any potential plan or appeal.
What deadline does Arcadia Biosciences (RKDA) face to regain Nasdaq compliance?
Arcadia has 45 calendar days, until October 15, 2026, to submit a plan to Nasdaq to achieve and sustain compliance with the $2,500,000 Stockholders’ Equity Requirement for the Nasdaq Capital Market.
How much stockholders’ equity did Arcadia Biosciences (RKDA) report?
In its Form 10-Q for the period ended June 30, 2026, Arcadia reported $633,000 in stockholders’ equity, which is below the Nasdaq Capital Market’s required $2,500,000 minimum for continued listing.
What extension could Nasdaq grant Arcadia Biosciences (RKDA) if its plan is accepted?
If Nasdaq accepts Arcadia’s compliance plan, Nasdaq may grant up to 180 calendar days from the date of the notice letter for the company to evidence compliance with the Stockholders’ Equity Requirement.
What options does Arcadia Biosciences (RKDA) have if Nasdaq rejects its compliance plan?
If Nasdaq does not accept Arcadia’s plan, the company may appeal to a Nasdaq Hearings Panel under Listing Rule 5815(a). A hearing request ordinarily stays any suspension or delisting action until a written panel decision is issued.
AI-generated analysis. How Rhea-AI works. Not financial advice.
